WuXi XDC Cayman Inc (2268.HK) stock analysis

In our weekly check, WuXi XDC Cayman Inc is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 20 pass, warnings: 1, red flags: 3.

About WuXi XDC Cayman Inc

WuXi XDC Cayman Inc is a Healthcare company (Medical - Diagnostics & Research) based in China, listed on HKSE as 2268.HK.

What our checks show for 2268.HK

Red flags

• The price swings a lot: 53.6% annual volatility. Expect large ups and downs.
• The stock has fallen as much as 61% from a peak. Would you have held through that?
• The share count grew by 22.6% in 2 years: each shareholder owns a smaller slice.

Warning signs

• The price is 46.3 times earnings (P/E): the market already pays for a lot of future growth.

Strengths

• Debt is low: 0.05x equity.
• Operating profit covers interest 14.4 times over.
• The net margin rose by 7.3 points over 5 years, to 24.9%.
• Operating cash flow is 1.25x net profit: the profit arrives as real cash.
• Analysts expect earnings per share to grow about 40.6% a year over the next years.
• Analysts expect revenue to grow about 41.6% a year over the next years.

Similar companies

NTRA · A · WAT · IQV · DHR · IDXX

Questions

What grade does WuXi XDC Cayman Inc (2268.HK) have?

In our weekly check, WuXi XDC Cayman Inc is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 20 pass, warnings: 1, red flags: 3. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 2268.HK stock?

This week's biggest flags for WuXi XDC Cayman Inc: Very volatile, Deep past fall, Share dilution. In total 4 of 24 checks show a warning or a red flag.

What does WuXi XDC Cayman Inc do?

WuXi XDC Cayman Inc is a Healthcare company (Medical - Diagnostics & Research) based in China, listed on HKSE as 2268.HK.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-31

Open the full analysis